Casale Donn
Transaction: 07/01/2026
BUY
Change
+898,456
Price
$7.96
Filing
07/02/2026
Type
BUY
ARS Pharmaceuticals, Inc.
SPRY • Biotechnology
$5.62
▼ -0.05 (-0.88%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$558.14M
Growth
—
Cash Flow
1/5
Trend
Volatile
Evidence
Positive revenue growth · 45.5%Manageable debt level · 0.85Healthy liquidity · 7.28Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:11 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$5.62
Change-0.88%
Shares Out99.31M
Market Cap$558.14M
Enterprise Value$414.29M
52W Range4.91 - 15.09
Beta0.88
P/E-2.59
P/S4.77
P/B44.61
P/FCF-2.84
EV/Sales3.54
Price$5.62
Change-0.88%
Shares Out99.31M
Market Cap$558.14M
Enterprise Value$414.29M
52W Range4.91 - 15.09
Beta0.88
P/E-2.59
P/S4.77
P/B44.61
P/FCF-2.84
EV/Sales3.54
EV/EBITDA-1.98
EV/FCF-2.11
Earnings Yield-38.60%
FCF Yield-35.22%
Dividend Yield0.00%
Gross Margin75.77%
Oper. Margin-2.13%
Profit Margin-2.03%
Debt/Eq0.85
Current Ratio7.28
Quick Ratio7.06
Target$25.50
Target Upside353.74%
Target Median$25.50
Target Range25.00 - 26.00
Volume1.94M
Avg Volume1.91M
EPS Surprise-0.08
Investment DNA
How strong this company looks for long-term investors
43
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
20/100
Why this score▼
Positive revenue growth · 45.5%Manageable debt level · 0.85Healthy liquidity · 7.28Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 10 analyst votes · 2026-09-05
70/100
Bullish
Bullish
4
Hold
6
Bearish
0
Price Target
2026-08-14
Low
$25.00
Mean
$25.50
Median
$25.50
High
$26.00
Insider Transactions
Recent executive and insider activity
Shawver Laura
Transaction: 06/24/2026
BUY
Change
+30,000
Price
$10.54
Filing
06/26/2026
Type
BUY
SCHNEIDER PHILLIP M
Transaction: 06/24/2026
BUY
Change
+30,000
Price
$10.54
Filing
06/26/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Casale Donn | BUY | +898,456 | $7.96 | 07/01/2026 | 07/02/2026 |
| Shawver Laura | BUY | +30,000 | $10.54 | 06/24/2026 | 06/26/2026 |
| SCHNEIDER PHILLIP M | BUY | +30,000 | $10.54 | 06/24/2026 | 06/26/2026 |
| SAUNDERS BRENT L | BUY | +30,000 | $10.54 | 06/24/2026 | 06/26/2026 |
| Thompson Peter A. | BUY | +30,000 | $10.54 | 06/24/2026 | 06/26/2026 |
| Islam Saqib | BUY | +30,000 | $10.54 | 06/24/2026 | 06/26/2026 |
| Kelly Michael | BUY | +30,000 | $10.54 | 06/24/2026 | 06/26/2026 |
| Shah Pratik | BUY | +30,000 | $10.54 | 06/24/2026 | 06/26/2026 |
| Dadoo Rajeev | BUY | +30,000 | $10.54 | 06/24/2026 | 06/26/2026 |
| RA CAPITAL MANAGEMENT, L.P. | BUY | +30,000 | $10.54 | 06/24/2026 | 06/26/2026 |
| Fitzpatrick Alexander A | SELL | -3,355 | $10.00 | 06/12/2026 | 06/12/2026 |
| Karas Eric | SELL | -25,000 | $10.00 | 06/12/2026 | 06/12/2026 |
| Karas Eric | SELL | -25,000 | $1.50 | 06/12/2026 | 06/12/2026 |
| Casale Donn | OTHER | 0 | Not reported | 06/01/2026 | 06/01/2026 |
| Lowenthal Richard E | BUY | +240,000 | $11.49 | 01/02/2026 | 01/05/2026 |
| Tanimoto Sarina | BUY | +240,000 | $11.49 | 01/02/2026 | 01/05/2026 |
| Chakma Justin | BUY | +240,000 | $11.49 | 01/02/2026 | 01/05/2026 |
| Dorsey Brian | BUY | +240,000 | $11.49 | 01/02/2026 | 01/05/2026 |
| Fitzpatrick Alexander A | BUY | +240,000 | $11.49 | 01/02/2026 | 01/05/2026 |
| Karas Eric | BUY | +240,000 | $11.49 | 01/02/2026 | 01/05/2026 |